Here comes the blockbuster! Zhengda Tianqing's 16 billion plus products are not enough, and new lung cancer drugs "explode" the market by 100 billion

Wonderful content recently, China biopharmaceutical announced that its subsidiary, androtinib hydrochloride capsule (trade name: fukewei), an anti-tumor class 1 Chemical independently developed by Tianqing Pharmaceutical Co., Ltd., has obtained the drug registration approval issued by the State Drug Administration, which marks that the original research and innovation drugs in the field of cancer in China, which has attracted much attention, will soon be listed Zhengda Tianqing Pharmaceutical Co., Ltd has 16 over 100 million products, of which 2 have sales of over 1 billion yuan, supporting the parent company's "half sky" of China's biopharmaceutical performance Now with the approval of anlotini, the "king of first imitation" has been upgraded, and Zhengda Tianqing is on the road of "combination of innovation and imitation" Can it become the next Hengrui pharmaceutical?   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; line-height: 25.6px; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> why arotinib is so concerned? Arotinib is a new small molecule multi-target tyrosine kinase inhibitor, which can effectively act on VEGFR, PDGFR, FGFR, c-kit and other targets, and has dual effects of anti-tumor angiogenesis and tumor growth inhibition In addition, clinical studies have shown that arotinib is effective in the treatment of advanced non-small cell lung cancer (NSCLC) At present, Zhengda Tianqing Pharmaceutical Co., Ltd is actively carrying out multi center clinical trial research including the United States In the future, with the development of foreign markets and the approval of multiple indications, arotinib is expected to become another more than 1 billion varieties of the company Figure 1: market share of top 5 PKI brands in 2013-2016 According to the data of minenet, in 2016, the terminal anti-tumor and immunomodulator drug market of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) was 102.386 billion yuan, of which 6.632 billion yuan was protein kinase inhibitor drug market, an increase of 15.59% over the previous year Among the top 5 brands, Novartis, AstraZeneca, Bayer and other foreign enterprises occupy the main market, and there is a large space to replace imports in China In recent years, with the continuous listing of domestic products, the market share of Novartis, AstraZeneca, Roche and other foreign enterprises has shown a downward trend As the only domestic enterprise, the market share of Beida pharmaceutical industry has remained stable With the approval of the listing of Zhengda Tianqing anrotini, the overall market pattern of protein kinase inhibitors may change greatly For Chia Tai Tianqing pharmaceutical industry, the successful listing of androtinib is a major breakthrough It is the first innovative small molecule drug developed by the company in accordance with international R & D process and standards, and also the anti-cancer drug with the largest R & D investment so far Its successful listing not only brings huge potential market space, but also marks a solid step in the transformation of the company's strategy from "combination of innovation and imitation" to "combination of innovation and imitation"   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; line-height: 25.6px; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> 16 over 100 million products, supporting the" half sky "of the parent company's performance Zhengda Tianqing Pharmaceutical Co., Ltd is a subsidiary of China biopharmaceutical industry Under the same business segment, there are also subsidiaries such as Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., Qingdao Zhengda Fenghai Pharmaceutical Co., Ltd., Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd., Shanghai General Pharmaceutical Co., Ltd but in terms of product category and market performance, Zhengda Tianqing Pharmaceutical Co., Ltd is the best performing one Figure 2: performance of China's biopharmaceutical subsidiaries in 2017 (unit: 100 million yuan) (source: annual report of listed companies) According to the data of China's biopharmaceutical annual report in 2017, the company achieved operating revenue of 14.819 billion yuan and net profit of 3.654 billion yuan, up 9.42% and 33.9% respectively year on year Among them, the revenue of Zhengda Tianqing pharmaceutical industry reached 8.336 billion yuan, accounting for 56.25% of the total operating revenue of China's biopharmaceutical industry, and the net profit reached 2.283 billion yuan, accounting for 62.48% of the total net profit of China's biopharmaceutical industry Table 1: in 2017, Zhengda Tianqing Pharmaceutical Co., Ltd sold over 100 million products (source: annual report of listed companies, minenet database) The products in production of Zhengda Tianqing Pharmaceutical Co., Ltd cover liver disease, tumor, respiratory system, infection, digestive system and many other disease fields According to the data of 2017 annual report, in 2017, there were 16 products with annual sales of more than 100 million yuan in Zhengda Tianqing Pharmaceutical Co., Ltd., forming a "product group of 100 million yuan", including 2 products with annual sales of more than 1 billion yuan, respectively, the national class 1 new drug isoglycyrrhizic acid magnesium injection (commodity Tianqing Ganmei (Tianqing Ganmei) and the first entecavir dispersible tablet (trade name: Runzhong) in China Among the 16 over 100 million products, there are 7 drugs for liver disease, 6 for anti-tumor, 2 for anti infection and 1 for respiratory system Three of the seven hepatology drugs are the exclusive products of Zhengda Tianqing Pharmaceutical Co., Ltd., and two of them have a sales volume of more than 1 billion yuan It can be seen that hepatology is the leading field of the company Among the six anti-tumor drugs, desetabine for injection, imatinib mesylate capsule and dasatinib tablet are all the first imitations in China It can be seen that the company has also formed a unique product line in the anti-tumor field Figure 3: market share of top 5 systemic antiviral brands in 2013-2016 (source: terminal competition pattern of China's public medical institutions in minenet) Zhengda Tianqing's liver disease medication series consists of two categories: antiviral drugs and liver protection and enzyme reduction According to the data of minenet, in 2016, among the top 5 brands of systemic antiviral drugs for public medical institutions in China, Zhengda Tianqing Pharmaceutical Co., Ltd had two products on the list, namely entecavir dispersible tablet (trade name: Runzhong) and adefovir dipivoxil capsule (trade name: Zhengzheng) Among them, Runzhong ranked first with 23% Entecavir dispersible tablet is a new generation of oral guanine nucleoside analogues, which is mainly used for the treatment of hepatitis B virus infection It was first imitated on the market in 2005 and is one of the widely used anti hepatitis B drugs In recent years, Runzhong's market share has continued to rise In 2015, it was equal with the original research manufacturer, Bristol Myers Squibb In 2016, it surpassed the original research manufacturer by absolute advantage and won the first place Table 2: market share of top 10 brands of bile and liver disease therapeutic drugs (source: minenet China public medical institutions terminal competition pattern) minenet data shows that in 2016, among the top 10 brands of Chinese public medical institutions terminal bile and liver disease therapeutic drugs, two products of Zhengda Tianqing pharmaceutical industry were on the list, magnesium isoglycyrrhizate injection (trade name: Tianqing Ganmei) With 19.48% ranking first, diammonium glycyrrhizinate enteric coated capsule (trade name: Tianqing Ganping) ranking seventh with 2.71%, both of which are exclusive products of Zhengda Tianqing pharmaceutical industry Isoglycyrrhizic acid magnesium injection is a patent drug, which is extracted from Glycyrrhiza uralensis and separated from Glycyrrhiza uralensis It can be used in the treatment of acute and chronic hepatitis with elevated glutamic pyruvic transaminase Tianqing Ganmei is a class 1 new drug independently developed by Zhengda Tianqing Pharmaceutical Co., Ltd and its compound patent has won the gold medal of Chinese patent   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; line-height: 25.6px; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> once the" king of first imitation "was upgraded, and class 1 new drugs will break out in the future "First imitation" is the strategic plan that Zhengda Tianqing Pharmaceutical Co., Ltd has always adhered to, and it is also the company's biggest competitive advantage in the market The latest application for first imitation took place on May 2, when zenirik acetate injection (trade name is Qingle) obtained the drug registration approval and became the first imitation of zenirik acetate injection in China However, with the approval and listing of androtini, Zhengda Tianqing is moving from the past "combination of imitation and creation" to "combination of creation and imitation" Zhengda Tianqing pharmaceutical said that in the past, the company's resource allocation for innovative drugs and generic drugs was 3:7, and by 2015 it had been 5:5 In the future, it plans to increase the proportion to 7:3 by 2020 According to the data of Zhengda Tianqing official website, the annual R & D investment of the company exceeds 8.5% of the annual sales revenue budget, with more than 1000 independent R & D personnel At present, there are more than 180 research projects, including more than 40 innovative drugs and more than 20 biological drugs, involving liver disease, tumor, respiration, infection, cardiovascular and cerebrovascular diseases Table 3: some class 1 new drugs (excluding APIs) in clinical phase I of Zhengda Tianqing Pharmaceutical (source: minenet database) According to the data of minenet global drug R & D database and med China drug review database 2.0, there are more than 10 class 1 new drugs in clinical phase I in the research products of Zhengda Tianqing pharmaceutical industry, most of which are anti-tumor drugs It can be seen that the company will further improve its competitiveness in the field of anti-tumor while ensuring its position in the field of traditional liver diseases, and form a rich product chain Heavyweight new drugs have been approved, more than 180 projects under research, more than one class 1 new drugs have been approved clinically All of these show that Zhengda Tianqing has officially embarked on the road of original new drugs In the future, with a perfect R & D system, strong R & D investment and rich research pipeline, we believe that Zhengda Tianqing can go far on this road Data source: minenet database, annual report of listed companies, official website of listed companies, etc